Abstract
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients
Introduction
Schizophrenia affects approximately 0.5–1% of the population, and achieving early, effective treatment is paramount for long-term social and cognitive outcomes. However, a significant challenge exists: roughly 30% of patients are "treatment-resistant" (TRS), failing to respond to standard antipsychotic medications. For these individuals, clozapine is the only evidence-based pharmacological option. Due to its potential for severe side effects, clozapine is typically reserved as a last resort, often after years of ineffective trials with other drugs. This delay in effective treatment leads to prolonged psychosis and poorer long-term prognoses. This study investigates whether molecular evidence, specifically polygenic risk scores (PRS), can identify TRS patients earlier in their clinical course.
Methodology
The researchers conducted a retrospective analysis of 804 schizophrenia patients, categorized into two groups: those with a history of clozapine treatment (Cloz+, $n=434$), serving as a proxy for TRS, and those without (Cloz-, $n=370$), representing responders to standard medication.
Genetic risk was quantified using a polygenic risk score (PRS), which aggregates the effects of numerous small-impact genetic variants identified in a major 2011 genome-wide association study (GWAS) of schizophrenia. The study compared these groups based on their PRS and various premorbid clinical features, including age of onset, premorbid social functioning (PSF), substance abuse, and family history. Regression models were employed to evaluate the relationship between genetic burden, clinical phenotypes, and treatment resistance.
Results
The study found that treatment-resistant schizophrenia is associated with a higher genetic burden, suggesting it may represent a biologically distinct, more severe subgroup of the disorder.
Genetic Risk Elevation
Analysis revealed that the PRS was significantly elevated in the Cloz+ (TRS) group compared to the Cloz- group ($P = 0.02$). The highest genetic risk scores were observed in an "extreme" phenotype: patients who were not only treatment-resistant but also failed to respond to clozapine itself (ETRS+), particularly those with poor PSF and early disease onset ($P = 0.04$).
Clinical and Genetic Interplay
Cloz+ patients exhibited significantly worse clinical histories, including a higher frequency of poor premorbid social functioning ($P = 8.1 \times 10^{-5}$; OR = 1.85), an earlier average age-of-onset (23.0 vs. 25.5 years; $P = 3.0 \times 10^{-6}$), and a more insidious disease onset ($P = 4.4 \times 10^{-3}$). Interestingly, when clinical variables like poor PSF were included in regression models alongside the PRS, the statistical significance of the genetic score decreased. This suggests that these severe clinical features are likely direct phenotypic manifestations of the underlying high genetic load.
Discussion and Future Directions
These findings provide the first molecular evidence that a higher polygenic risk for schizophrenia is directly associated with treatment resistance. Identifying this genetically severe subgroup early could allow clinicians to fast-track patients to clozapine, potentially avoiding years of ineffective treatment.
However, the study notes limitations, including a relatively small sample size ($n=804$) which may have limited the detection of some associations, such as family history. Additionally, the PRS accuracy depends on the composition of the original GWAS discovery sample. Future research with larger cohorts is necessary to validate these findings and refine genetic and clinical predictors into a robust screening tool for clinical practice.
Summary updated